policy
NICE Reviews Medical Cannabis Evidence for Chronic Pain
The National Institute for Health and Care Excellence has opened a formal evidence review for cannabis-based medicines in chronic neuropathic pain, with.
NICE has initiated a technology appraisal for cannabis-based medicinal products in chronic neuropathic pain — a category that would cover the majority of current UK medical cannabis patients. The review comes after sustained pressure from patient advocacy organisations and a growing body of clinical evidence from the UK ACCESS programme.
More Policy News
Policy
Medical Cannabis Import Rules: UK Border Force Updated Guidelines
UK Border Force has issued updated operational guidance for the importation of cannabis-based medicinal products, clari…
05 Mar 2026
Policy
Post-Brexit UK Cannabis Regulation: Charting an Independent Course
With the UK no longer bound by EU pharmaceutical directives, the MHRA and Home Office have been developing a distinctly…
17 Feb 2026
Policy
New Prescriber Training Programme Aims to Double UK Cannabis Doctors
The Academy of Medical Cannabis has launched an expanded training programme targeting 1,000 new specialist prescribers …
03 Feb 2026
More News
product
Adven EMT-3: UK Availability, Price and Prescribing Guide
07 Jun 2026
product
Bedrolite CBD Oil UK: Prices, Availability and Patient Guide
07 Jun 2026
news
Alternaleaf UK: Full Product List, Prices and Patient Review 2026
07 Jun 2026
regulation
Bedrocan Expands UK Distribution Network
26 May 2026